177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 44, Issue 1, 2017, Pages 81-91

  Yadav, Madhav Prasad ^a   Ballal, Sanjana ^a   Tripathi, Madhavi ^a   Damle, Nishikant Avinash ^a   Sahoo, Ranjit Kumar ^b   Seth, Amlesh ^a   Bal, Chandrasekhar ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

177Lu DKFZ PSMA 617 radionuclide therapy; Efficacy; mCRPC; Quality of life

Indexed keywords

ANALGESIC AGENT; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; DOCETAXEL; GALLIUM 68; HEMOGLOBIN; LUTETIUM 177; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; 177LU-DKFZ-617; 177LU-PSMA-617; DIPEPTIDE; ORGANOMETALLIC COMPOUND; PEPTIDE; SINGLE HETEROCYCLIC RINGS;

ADULT; AGED; ARTICLE; BIOCHEMICAL ANALYSIS; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; HEMATOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION; LIVER FUNCTION TEST; MALE; METABOLISM; METASTASIS; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; PROSPECTIVE STUDY; QUALITY OF LIFE; RADIOISOTOPE DIAGNOSIS; RADIOISOTOPE THERAPY; SCORING SYSTEM; TREATMENT RESPONSE; VISUAL ANALOG SCALE; CLINICAL TRIAL; MIDDLE AGED; PROCEDURES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PSYCHOLOGY; RADIATION INJURIES; THERANOSTIC NANOMEDICINE; TREATMENT OUTCOME;

ADULT; AGED; DIPEPTIDES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOMETALLIC COMPOUNDS; PEPTIDES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; QUALITY OF LIFE; RADIATION INJURIES; RADIOPHARMACEUTICALS; THERANOSTIC NANOMEDICINE; TREATMENT OUTCOME;

EID: 84981294507     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-016-3481-7     Document Type: Article

References (23)

1. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systemic review. Int J Clin Pract. 2011;65:1180–92.
2. Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Urol Oncol. 2010;17(Suppl 2):S72–9.
3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.
4. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.
5. Benesová M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailormade DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914–20.
6. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys. 2003;85:294–310.
7. Van Essen M, Krenning EP, de Jong M, Valkema R, Kwekkeboom DJ. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol. 2007;46:723–34.
8. Kabasakal L, AbuQbeitah M, Aygün A, Yeyin N, Ocak M, Demirci E, et al. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:1976–83.
9. Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, et al. Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:42–51.
10. Richard L. Wahl1, Heather Jacene, Yvette Kasamon, and Martin A. Lodge. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009; 50:5 (Suppl).
11. Green S, Weiss GR. Southwest Onology group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992;10:239–53.
12. McCaffery M, Pasero C. Pain: clinical manual. St. Louis: Mosby;1999.p.16.
13. Crooks V, Waller S, Smith T, Hahn TJ. The use of Karonofsky Performance Scale in determining outcomes and risk in geriatric outpatients. J Gerontol. 1991;46:139–44.
14. Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, et al. Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2013;19:5182–91.
15. Friedrich SW, Lin SC, Stoll BR, Baxter LT, Munn LL, Jain RK. Antibody-directed effector cell therapy of tumors: analysis and optimization using a physiologically based pharmacokinetic model. Neoplasia. 2002;4:449–63.
16. Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowski MI, et al. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies usng 90Y- and 177Lu-labelled J591 antibodies specific for prostate specific membrane antigen. J Nucl Med. 2005;46:850–8.
17. Heck MM, Retz M, D’Alessandria C, Rauscher I, Scheidhauer K, Maurer T, Storz E, et al. Systemic radioligand therapywith 177Lu-PSMA-I&T in patients with metastatic castration –resistant prostate cancer. J Urol. 2016.
18. Schmitz MD, Padula GD, Chun PY, Davis AT. Normalization of prostate specific antigen in patients treated with intensity modulated radiotherapy for clinically localized prostate cancer. Radiat Oncol. 2010;5:80.
19. Lorenzo GD, Buonerba C, Faiella A, Rescigno P, Rizzo M, Autorino R, et al. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int. 2010;107:234–9.
20. Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. Lutetium-177 PSMA radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016.
21. Ahmadzadehfar H, Rahbar K, Kurpig S, Bogemann M, Claesener M, Eppard E, et al. Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castration-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;5:36.
22. Harrison MR, Wong TZ, Armstrong AJ, George DJ. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res. 2013;5:1–14.
23. Parker C, Heinrich D, O’Sullivan JM, et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol. 2012;30(Suppl 5):Abstr 8.